These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 25589652)

  • 21. Reverse genetics approaches to combat pathogenic arenaviruses.
    de la Torre JC
    Antiviral Res; 2008 Dec; 80(3):239-50. PubMed ID: 18782590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Innate and adaptive immune control of genetically engineered live-attenuated arenavirus vaccine prototypes.
    Pinschewer DD; Flatz L; Steinborn R; Horvath E; Fernandez M; Lutz H; Suter M; Bergthaler A
    Int Immunol; 2010 Sep; 22(9):749-56. PubMed ID: 20584765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus.
    Sánchez AB; Perez M; Cornu T; de la Torre JC
    J Virol; 2005 Sep; 79(17):11071-81. PubMed ID: 16103158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
    Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
    mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development.
    Lorenzo MM; Nogales A; Chiem K; Blasco R; Martínez-Sobrido L
    Microbiol Spectr; 2022 Jun; 10(3):e0027222. PubMed ID: 35583360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactome analysis of the lymphocytic choriomeningitis virus nucleoprotein in infected cells reveals ATPase Na+/K+ transporting subunit Alpha 1 and prohibitin as host-cell factors involved in the life cycle of mammarenaviruses.
    Iwasaki M; Minder P; Caì Y; Kuhn JH; Yates JR; Torbett BE; de la Torre JC
    PLoS Pathog; 2018 Feb; 14(2):e1006892. PubMed ID: 29462184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens.
    Penaloza MacMaster P; Shields JL; Alayo QA; Cabral C; Jimenez J; Mondesir J; Chandrashekar A; Cabral JM; Lim M; Iampietro MJ; Provine NM; Bricault CA; Seaman M; Orlinger K; Aspoeck A; Fuhrmann G; Lilja AE; Monath T; Mangeat B; Pinschewer DD; Barouch DH
    Vaccine; 2017 Jan; 35(1):1-9. PubMed ID: 27899229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
    Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL
    Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arenavirus extinction through lethal mutagenesis.
    de la Torre JC
    Virus Res; 2005 Feb; 107(2):207-14. PubMed ID: 15649566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo characterizations of pichinde viral nucleoprotein exoribonuclease functions.
    Huang Q; Shao J; Lan S; Zhou Y; Xing J; Dong C; Liang Y; Ly H
    J Virol; 2015 Jul; 89(13):6595-607. PubMed ID: 25878103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocytic choriomeningitis arenavirus requires cellular COPI and AP-4 complexes for efficient virion production.
    Byford O; Shaw AB; Tse HN; Todd EJAA; Álvarez-Rodríguez B; Hewson R; Fontana J; Barr JN
    J Virol; 2024 Mar; 98(3):e0200623. PubMed ID: 38334330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein.
    Pinschewer DD; Perez M; Sanchez AB; de la Torre JC
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7895-900. PubMed ID: 12808132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
    Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses.
    Rojek JM; Sanchez AB; Nguyen NT; de la Torre JC; Kunz S
    J Virol; 2008 Aug; 82(15):7677-87. PubMed ID: 18508885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Reverse Genetics for the Prototype New World Mammarenavirus Tacaribe Virus.
    Ye C; de la Torre JC; Martínez-Sobrido L
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological Characterization of Conserved Residues within the Cytoplasmic Tail of the Pichinde Arenaviral Glycoprotein Subunit 2 (GP2).
    Shao J; Huang Q; Liu X; Di D; Dileepan M; Brisse M; Ly H; Liang Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein.
    Hany M; Oehen S; Schulz M; Hengartner H; Mackett M; Bishop DH; Overton H; Zinkernagel RM
    Eur J Immunol; 1989 Mar; 19(3):417-24. PubMed ID: 2468501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel antiviral strategies to combat human Arenavirus infections.
    Kunz S; de la Torre JC
    Curr Mol Med; 2005 Dec; 5(8):735-51. PubMed ID: 16375709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of recombinant arenavirus for vaccine development in FDA-approved Vero cells.
    Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L
    J Vis Exp; 2013 Aug; (78):. PubMed ID: 23928556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.